The Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

“Glioma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioma Market.

Some of the key takeaways from the Glioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Glioma treatment therapies with a considerable amount of success over the years. 
• Glioma companies working in the treatment market are TCRCure Biopharma Ltd., Cytovia Therapeutics, Evgen Pharma, Immunomic Therapeutics, Chimerix, Xynomic Pharmaceuticals, Celgene, Incyte Corporation, MimiVax, Medicenna Therapeutics, Denovo Biopharma, Genentech/Roche, Novartis, InnoKeys PTE Ltd., and others, are developing therapies for the Glioma treatment 

• Emerging Glioma therapies in the different phases of clinical trials are- I301, CYT501, SFX-01, ITI-1001, PCI 24781, ONC206,  Pomalidomide, Retifanlimab, SurVaxM, MDNA55, ONC201, Enzastaurin, Avastin, Tafinlar + Mekinist, Nimotuzumab, and others are expected to have a significant impact on the Glioma market in the coming years.   
• On March 16, 2023, The combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) has been approved by the Food and Drug Administration for pediatric patients aged one year and above who have low-grade glioma (LGG) with a BRAF V600E mutation and need systemic therapy. Additionally, the FDA approved new oral versions of both medications for patients who have trouble swallowing pills.
• On June 22, 2022, For the treatment of adult and pediatric patients ≥ 6 years old with unresectable or metastatic solid tumors with BRAF V600E mutation that have progressed after prior treatment and have no adequate alternative treatment options, the Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis).

Glioma Overview

The most prevalent type of glial cell-derived central nervous system (CNS) tumor is called a glioma. Gliomas are detected in six cases per 100,000 persons in the United States each year. Gliomas are tumors that infiltrate the surrounding brain tissue quite widely.

Get a Free Sample PDF Report to know more about Glioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioma-pipeline-insight

Emerging Glioma Drugs Under Different Phases of Clinical Development Include:

• I301: TCRCure Biopharma Ltd.
• CYT501: Cytovia Therapeutics
• SFX-01: Evgen Pharma
• ITI-1001: Immunomic Therapeutics
• PCI 24781: Xynomic Pharmaceuticals
• ONC206: Chimerix
• Pomalidomide: Celgene
• Retifanlimab: Incyte Corporation
• SurVaxM: MimiVax
• MDNA55: Medicenna Therapeutics
• ONC201: Chimerix
• Enzastaurin: Denovo Biopharma
• Avastin: Genentech/Roche
• Tafinlar + Mekinist: Novartis
• Nimotuzumab: InnoKeys PTE Ltd.

Glioma Route of Administration

Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Glioma Molecule Type

Glioma Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Glioma Pipeline Therapeutics Assessment

• Glioma Assessment by Product Type
• Glioma By Stage and Product Type
• Glioma Assessment by Route of Administration
• Glioma By Stage and Route of Administration
• Glioma Assessment by Molecule Type
• Glioma by Stage and Molecule Type

DelveInsight’s Glioma Report covers around 130+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioma product details are provided in the report. Download the Glioma pipeline report to learn more about the emerging Glioma therapies

Some of the key companies in the Glioma Therapeutics Market include:

Key companies developing therapies for Glioma are – Novartis, Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly, and Company, and others.

Glioma Pipeline Analysis:

The Glioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment.
• Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioma drugs and therapies

Glioma Pipeline Market Drivers

• Rise in prevalence, targeted therapy approach to improve the effectiveness of glioma treatment, identification of potential drug targets with genomic and proteomic analysis are some of the important factors that are fueling the Glioma Market.

Glioma Pipeline Market Barriers

• However, poor prognosis and high rate of recurrence, lack of patient enrollment in glioma based clinical trials and other factors are creating obstacles in the Glioma Market growth.

Scope of Glioma Pipeline Drug Insight    

• Coverage: Global
• Key Glioma Companies: TCRCure Biopharma Ltd., Cytovia Therapeutics, Evgen Pharma, Immunomic Therapeutics, Chimerix, Xynomic Pharmaceuticals, Celgene, Incyte Corporation, MimiVax, Medicenna Therapeutics, Denovo Biopharma, Genentech/Roche, Novartis, InnoKeys PTE Ltd., and others
• Key Glioma Therapies: I301, CYT501, SFX-01, ITI-1001, PCI 24781, ONC206,  Pomalidomide, Retifanlimab, SurVaxM, MDNA55, ONC201, Enzastaurin, Avastin, Tafinlar + Mekinist, Nimotuzumab, and others
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers 

Request for Sample PDF Report for Glioma Pipeline Assessment and clinical trials

Table of Contents

1. Glioma Report Introduction

2. Glioma Executive Summary

3. Glioma Overview

4. Glioma- Analytical Perspective In-depth Commercial Assessment

5. Glioma Pipeline Therapeutics

6. Glioma Late Stage Products (Phase II/III)

7. Glioma Mid Stage Products (Phase II)

8. Glioma Early Stage Products (Phase I)

9. Glioma Preclinical Stage Products

10. Glioma Therapeutics Assessment

11. Glioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioma Key Companies

14. Glioma Key Products

15. Glioma Unmet Needs

16 . Glioma Market Drivers and Barriers

17. Glioma Future Perspectives and Conclusion

18. Glioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services